Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Crescent Biopharma will present a trial-in-progress poster for its ASCEND study of CR-001 at the ASCO 2026 Annual Meeting in Chicago. The global Phase 1/2 trial evaluates the PD-1 x VEGF bispecific antibody in multiple solid tumors, including NSCLC, gastrointestinal, and gynecological cancers, with enrollment ongoing up to 290 patients.
Key figures
- Drug Name
- CR-001
- Phase Of Trial
- Phase 1/2
- Max enrollment
- 290
- Next data readout
- Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.